Sahak, Judith C.
HRN: 07-33-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/11/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
03/11/2023
03/18/2023
IV
500mg
Q8
Cholelithiasis Cholecystitis
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes